1. Home
  2. OUST vs COLL Comparison

OUST vs COLL Comparison

Compare OUST & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ouster Inc.

OUST

Ouster Inc.

HOLD

Current Price

$24.98

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$45.71

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OUST
COLL
Founded
2015
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
OUST
COLL
Price
$24.98
$45.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$34.80
$51.17
AVG Volume (30 Days)
1.9M
493.0K
Earning Date
11-04-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.63
Revenue
$137,298,000.00
$757,067,000.00
Revenue This Year
$35.72
$26.17
Revenue Next Year
$35.65
$3.65
P/E Ratio
N/A
$27.99
Revenue Growth
30.20
26.34
52 Week Low
$6.34
$23.23
52 Week High
$41.65
$50.79

Technical Indicators

Market Signals
Indicator
OUST
COLL
Relative Strength Index (RSI) 48.27 45.08
Support Level $23.53 $44.43
Resistance Level $28.08 $48.29
Average True Range (ATR) 1.95 2.08
MACD -0.05 -0.20
Stochastic Oscillator 17.92 25.32

Price Performance

Historical Comparison
OUST
COLL

About OUST Ouster Inc.

Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: